The approval of weight loss drug Zepbound for sleep apnea treatment in obese adults by Health Canada has sparked concerns about financial risks for benefits plan sponsors, according to Joseph Koo, assistant vice-president of health solutions and national pharmacist at Aon. While the medication represents a significant clinical advancement for this specific group, Koo emphasizes that the use of continuous positive airway pressure (CPAP) machines remains the most cost-effective initial treatment for most employees with obstructive sleep apnea. He argues that Zepbound should be reserved for patients who also require weight management or cannot tolerate CPAP, rather than becoming a widespread replacement for the more affordable and immediate CPAP therapy.
Koo highlights the cost disparity between the two treatments, noting that even with maintenance and supply costs, the total expense of treating obstructive sleep apnea with CPAP machines is significantly lower than the drug costs associated with Zepbound. To mitigate financial risks, employers should carefully consider the cost-effectiveness of Zepbound's expanded treatment indication. Koo suggests that clear criteria, such as documented sleep studies, body mass index thresholds, and prior authorization, are crucial to prevent indefinite therapies from imposing perpetual financial burdens on health plans.
One of the challenges plan sponsors face, Koo points out, is the lack of cost control based on indication within the current pharmacy benefit manager or carrier technology. Every new indication for Zepbound opens another door into the formulary for the same expensive drug, potentially leading to unintended and costly coverage decisions. This issue is particularly relevant given the expanded use of GLP-1 drugs beyond weight management, as discussed in a recent report.
In conclusion, the approval of Zepbound for sleep apnea treatment raises important considerations for benefits plan sponsors. By carefully evaluating cost-effectiveness and implementing clear criteria, employers can navigate the financial implications of this new indication while ensuring appropriate and sustainable coverage for their employees.
